| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HHG; LHR; LCGR; LGR2; ULG5; LHRHR; LSH-R; LH/CGR; LH/CG-R |
| Entrez GeneID | 3973 |
| clone | 8G9A2 |
| WB Predicted band size | 78.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | LHR-29 from ATCC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LHCGR(黄体生成素/绒毛膜促性腺激素受体)抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*Autoantibodies to luteinizing hormone receptor in women with infertility*
**作者**：Jia, X., et al.
**摘要**：该研究探讨了LHCGR自身抗体在不孕症患者中的作用，发现部分不明原因不孕女性血清中存在抗LHCGR抗体，可能通过干扰受体信号传导影响卵泡发育和排卵。
2. **文献名称**：*Anti-LHCGR antibodies in adrenal tumors: Diagnostic and therapeutic implications*
**作者**：Rao, C.V., et al.
**摘要**：研究发现肾上腺皮质肿瘤组织中LHCGR异常表达，开发了特异性单克隆抗体用于病理诊断，并探索了抗体靶向治疗在抑制肿瘤生长中的潜在效果。
3. **文献名称**：*Monoclonal antibody targeting LHCGR enhances ovarian cancer cell apoptosis*
**作者**：Zhang, Y., et al.
**摘要**：该文献报道了一种靶向LHCGR胞外域的单克隆抗体，在体外实验中显示其能阻断配体结合并诱导卵巢癌细胞凋亡，提示其作为卵巢癌靶向治疗的潜力。
(注：以上文献信息为示例性内容，实际引用需以具体论文数据为准。)
The luteinizing hormone/choriogonadotropin receptor (LHCGR) is a G protein-coupled receptor (GPCR) critical for reproductive physiology. It binds luteinizing hormone (LH) and chorionic gonadotropin (hCG), triggering cAMP/PKA signaling pathways that regulate ovulation, testosterone synthesis in Leydig cells, and corpus luteum maintenance. LHCGR antibodies are autoantibodies targeting this receptor, often implicated in autoimmune reproductive disorders.
In women, these antibodies may disrupt ovarian function, leading to conditions like premature ovarian insufficiency (POI) or infertility by blocking hormone-receptor interaction or downregulating receptor activity. In men, they can impair testosterone production, contributing to hypogonadism. LHCGR antibodies are also studied in gestational disorders, as hCG-LHCGR signaling is vital for pregnancy maintenance.
Clinically, LHCGR antibody detection (via immunoassays or cell-based bioassays) aids in diagnosing autoimmune reproductive dysfunction. Research explores their role in IVF outcomes and recurrent pregnancy loss. Additionally, therapeutic LHCGR-targeting antibodies are investigated in oncology, as LHCGR is abnormally expressed in some hormone-sensitive cancers. However, distinguishing pathogenic antibodies from benign autoantibodies remains challenging, necessitating functional studies to confirm their clinical relevance. Current management may involve immunosuppression or assisted reproductive technologies, though targeted therapies are under development.
×
